Vemurafenib in Chinese patients with BRAF(V600) mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study

BACKGROUND: Melanoma is a rare, deadly disease without effective treatment options in China. Vemurafenib is a selective inhibitor of oncogenic BRAF(V600) kinase approved in more than 90 countries, based on results obtained primarily in Caucasian patients. Limited data are available regarding the eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Si, Lu, Zhang, Xiaoshi, Xu, Zhen, Jiang, Qiudi, Bu, Lilian, Wang, Xuan, Mao, Lili, Zhang, Weijiang, Richie, Nicole, Guo, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934791/
https://www.ncbi.nlm.nih.gov/pubmed/29724167
http://dx.doi.org/10.1186/s12885-018-4336-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934791/
https://www.ncbi.nlm.nih.gov/pubmed/29724167
http://dx.doi.org/10.1186/s12885-018-4336-3

Ejemplares similares